Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Cisticid vs Biltricide in Healthy Males
NCT03437447Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of praziquantel in schistosomiasis (3 arms), sponsored by Merck KGaA. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration and Maximum Observed Plasma Concentration. Started Jun 2018; status: completed.
02
Drugs
praziquantel
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on NCT03437447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437447.